Phase 1 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have experienced a gradual and ongoing decline in memory that has been noticed by themselves or someone who knows them well, lasting 6 months or more, consistent with a diagnosis of Alzheimer's disease dementia
• People whose score on a standard memory and thinking test (called the Mini Mental State Examination) falls between 16 and 24 out of 30
• People whose blood test results meet specific protein markers related to Alzheimer's disease, as defined by the organisation running the trial (confirm with trial site)
• People whose body weight relative to their height (BMI) is between 17 and 32 at the time of screening
• Women who are not able to become pregnant, and men who are willing to use effective contraception for the duration of the study
• People who have adequate reading ability, vision, and hearing to complete study tasks throughout the trial
• People who have at least one, and up to two, support persons (such as a family member or carer) who spend at least 10 hours per week with them

Who may not be able to join:

• People for whom an MRI scan is not safe, including those with claustrophobia or certain metal implants or a cardiac pacemaker
• People whose screening MRI scan shows significant abnormal findings
• People with a history of suicidal behaviour, a past suicide attempt, or current thoughts of suicide
• People with a history of severe or ongoing allergic reactions, hypersensitivity to vaccines or immunoglobulins, two or more serious drug allergies, intolerance to topical corticosteroids, or severe reactions after receiving treatments
• People with a current serious or unstable medical condition affecting the liver, kidneys, digestive system, lungs, heart, nervous system (other than Alzheimer's disease), mental health, hormones, immune system, or blood
• People who are currently being treated with, or have received, a type of biological medicine called a monoclonal antibody within the past 3 months or within 5 half-lives of that medicine (whichever period is longer)
• People for whom a lumbar puncture (a procedure to collect fluid from around the spine) would not be medically appropriate (confirm with trial site)
• People who are currently taking part in another clinical study involving an experimental treatment or medical research that may conflict with this trial
• People who are currently using therapies that target amyloid (a protein associated with Alzheimer's disease); people who used such therapies more than one year ago may be considered, at the discretion of the treating doctor and the trial sponsor

Important: Always verify eligibility with the trial site directly before applying.